InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor

Stock Information for InflaRx N.V.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About InflaRx N.V.

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
InflaRx to Report First Quarter 2026 Results on May 7, 2026
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.